Enhancing the efficacy of sonodynamic therapy through modulation of autophagy.

Sonodynamic therapy (SDT), a noninvasive treatment modality that combines low intensity ultrasound with sonosensitizers, has shown significant potential in the treatment of cancer and metabolic diseases. However, SDT induced autophagy plays a dual role in disease progression, as it can promote either cell survival or cell death, and its effects are highly dependent on cell type and pathological context. This complexity underscores the urgent need for regulation of autophagy to optimize the therapeutic efficacy of SDT.

Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.

Clinical application of PD-1 and PD-L1 monoclonal antibodies (mAbs) is hindered by their relatively low response rates and the occurrence of drug resistance. Co-expression of B7-H3 with PD-L1 has been found in various solid tumors, and combination therapies that target both PD-1/PD-L1 and B7-H3 pathways may provide  additional therapeutic benefits. Up to today, however, no bispecific antibodies targeting both PD-1 and B7-H3 have reached the clinical development stage.

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain.

Dinutuximab (ch14.18) was the first approved monoclonal antibody against the tumor-associated antigen disialoganglioside GD2. Despite its success in treating neuroblastoma (NB), it triggers a significant amount of neuropathic pain in patients, possibly through complement-dependent cytotoxicity (CDC).